MEDICAL POLICY I. POLICY II. PRODUCT VARIATIONS POLICY TITLE AUDITORY BRAIN STEM IMPLANT POLICY NUMBER MP-1.085
|
|
- Derek Owens
- 5 years ago
- Views:
Transcription
1 Original Issue Date (Created): August 28, 2012 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 I. POLICY Unilateral use of an auditory brainstem implant (using surface electrodes on the cochlear nuclei) may be considered medically necessary in patients with neurofibromatosis type 2, who are 12 years of age or older, and who are rendered deaf due to bilateral resection of neurofibromas of the auditory nerve. An auditory brainstem implant is considered investigational for all other conditions including non-neurofibromatosis-type 2 indications. Bilateral use of an auditory brainstem implant is considered investigational. Penetrating electrode auditory brainstem implant (PABI) is considered investigational. There is insufficient evidence to support a conclusion supporting the health outcomes or benefits associated with the above procedures Cross-reference: MP Implantable Bone-Conduction and Bone-Anchored Hearing Prosthetic Devices MP Cochlear Implant MP Evaluation and Treatment of Hearing Loss MP Semi-Implantable and Fully Implantable Middle Ear Hearing Aid for Moderate to Severe Sensorineural Hearing Loss II. PRODUCT VARIATIONS [N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below [N] Capital Cares 4 Kids [N] PPO [N] HMO [Y] SeniorBlue HMO* [Y] SeniorBlue PPO* [N] Indemnity [N] SpecialCare [N] POS [Y] FEP PPO** Page 1
2 *Auditory Brainstem Implants are eligible for coverage. These devices are indicated only when hearing aids are medically inappropriate or cannot be utilized due to congenital malformations, chronic disease, severe sensorineural hearing loss, or surgery (Centers for Medicare and Medicaid Services (CMS) Medicare Benefit Policy Manual. Publication Chapter 16, Revision 39, Section 100. Hearing Aids and Auditory Implants). **Refer to FEP Medical Policy Manual MP Auditory Brainstem Implant. The FEP Medical Policy manual can be found at: III. DESCRIPTION/BACKGROUND The auditory brain stem implant is a device used to restore some hearing in patients with neurofibromatosis type II who are rendered deaf by bilateral removal of neurofibromas that involve the auditory nerve. The device consists of an external speech processor that provides auditory information to an electrical signal that is transferred to a receiver/stimulator that is implanted in the temporal bone. The receiver/stimulator is attached to an electrode array that is implanted on the surface of the cochlear nerve in the brainstem. The electrode stimulates multiple sites on the cochlear nucleus, which are then processed normally by the brain. One device has received approval by the U.S. Food and Drug Administration (FDA) for auditory brainstem implantation: the Nucleus 24 Auditory Brainstem Implant System (Cochlear Corporation). The speech processor and receiver are similar to the devices used in cochlear implants; the electrode array placed on the brainstem is the novel component of the device. The device is indicated for individuals 12 years of age or older who have been diagnosed with neurofibromatosis type 2 (NF2). IV. RATIONALE Unilateral Auditory Brainstem Implant In Patients With Neurofibromatosis Type 2 FDA approval of the Nucleus 24 Auditory Brainstem Implant System was based on results in a case series of 90 patients with neurofibromatosis type 2 (NF2), ages 12 years and older. (1, 2) Of the 90 subjects evaluated, 28 complications occurred in 26 patients; 26 of these complications resolved without surgical or extensive medical intervention. Two patients had infections of the postoperative flap requiring explantation of the device. A total of 60 patients had a minimum experience of 3 to 6 months with the device, and thus effectiveness outcomes were also evaluated. Overall device benefit was defined as a significant enhancement of lip-reading or an above-chance improvement on sound-alone tests. Based on this definition, a total of 95% patients (57 of 60) derived benefit from the device. While the use of an auditory brainstem implant (ABI) is associated with a very Page 2
3 modest improvement in hearing, this level of improvement is considered significant in this group of patients who have no other treatment options. Among the 90 patients receiving the implant, 16 did not receive auditory stimulation from the device postoperatively, either due to migration of the implanted electrodes or surgical misplacement. To place the electrode array on the surface of the cochlear nucleus, the surgeon must be able to visualize specific anatomical landmarks. Because large neurofibromas compress the brainstem and distort the underlying anatomy, it may be difficult or impossible for the surgeon to correctly place the electrode array. For this reason, patients with large, long-standing tumors may not benefit from the device. In 2012, Sanna and colleagues reported on 25 ABIs placed in 24 patients with NF2. (3) In this retrospective case study, patients were followed up for a range of 2 53 months. One patient died due to NF2 progression. Sound recognition was present in 19 patients, of whom 11 had some word recognition and 8 had good speech recognition (50% speech discrimination in 4 patients and % speech discrimination and telephone use in 4 patients). A multivariate analysis did not identify any factors that were statistically significant in predicting ABI performance outcomes. The authors also conducted a review of the literature on ABIs and found it difficult to compare outcomes as reporting methods and outcomes measured were inconsistent and imprecise. A retrospective review by Goffi- Gomez and colleagues report mixed results in audiologic outcomes in 5 adults (4 with NF2) and 4 children (all with non-tumor diseases) who received ABIs between 2005 and 2009 at a university center in Brazil. (4) Unilateral Auditory Brainstem Implant In Nontumor Patients In a 2004 study in Italy, V. Colletti and colleagues reported on the use of ABIs in patients with deafness unrelated to neurofibromatosis and who had a poor response to cochlear implants. (5) However, there are inadequate data from this study to permit scientific conclusions regarding this additional indication. V. Colletti and colleagues, in 2005, presented data from ABIs in 16 children and adults who had non-tumor diseases of the cochlear nerve or cochlea and 13 patients with NF2. (6) Ages ranged from 14 months to 70 years; the non-tumor group included patients with head trauma, complete cochlear ossification, 1 child with auditory neuropathy, and 5 children with bilateral cochlear nerve aplasia. Following implantation, the adult non-tumor group scored substantially higher than the patients with NF2 in open set speech perception tests. Some of the children showed dramatic improvements in word and sentence recognition over a 1-year follow-up. Short-term adverse effects included dizziness or tingling sensations in the leg, arm, and throat (20 of 29 patients). Page 3
4 Additional studies report improvement in hearing with ABIs in non-tumor patients; V. Colletti has reported results on 54 non-tumor patients, (7) and L. Colletti has reported results on 22 non-neurofibromatosis patients. (8) In a 2010 retrospective review, the authors previously cited, V. Colletti and colleagues, reported on the complications from ABI surgery in 83 adults and 31 children, 78 of whom had nontumor cochlear or cochlear nerve disorders. (9) The authors found complication rates were similar to cochlear implant surgery. Additionally, major and minor complications were significantly fewer in nontumor patients than in NF2 patients. These authors concluded ABIs can be used in a wider population of patients than only those with NF2. However, this review did not evaluate hearing outcomes. Sennaroglu et al., in 2009, reported on the use of ABIs in 11 prelingually deaf children ages months. (10) Results showed mean performance on the Meaningful Auditory Integration Scale improved in all patients. However, the results of this small study are described as only preliminary. Bilateral Auditory Brainstem Implants Nucleus 24 Auditory Brainstem Implant System (Cochlear Corporation) labeling states (1) The efficacy of bilateral implantation with the ABI has not been studied. No evidence was identified to support bilateral auditory brainstem stimulation. The studies included to date only included patients with unilateral auditory brainstem implantation. Penetrating Electrode Auditory Brainstem Implant In 2008, Otto et al. (11) conducted a prospective clinical trial (n=10) with patients with NF2 who received a penetrating electrode auditory brainstem implant (PABI) after vestibular schwannoma removal. The PABI is an extension of the ABI technology that uses surface electrodes on cochlear nuclei. PABI uses 8 or 10 penetrating microelectrodes in conjunction with a separate array of 10 to 13 surface electrodes. The PABI met the goals of lower threshold, increased pitch range, and high selectivity, but these properties did not result in improved speech recognition. These data are inadequate to draw conclusions regarding the effectiveness of PABI as compared to conventional ABI. Three general reviews were identified on ABI. Sennaroglu and Ziyal review the history and development of ABI, indications, side selection criteria, surgical options and audiological outcomes after ABI. (12) Colletti and colleagues discuss new developments on ABI specifically for NF2. (13) Schwartz and colleagues (14) discuss in a 2008 review article the future directions in central implants for hearing, including PABI, the use of ABI in nontumor patients, and the auditory midbrain implant. Page 4
5 Ongoing Clinical Trials A search of online site ClinicalTrials.gov identified one ongoing study on auditory brainstem implant. Study of Nucleus 24 Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects (NCT ) The purpose of this single-arm study is to analyze whether ABI surgery improves the hearing and quality of life of non-nf2 patients based on subjective and objective measures of their hearing before and after ABI surgery. This study has an estimated enrollment of 10 adult patients (with bilateral deafness who are not candidates for cochlear implants) at the Massachusetts Eye and Ear Infirmary in the U.S. The primary outcome measures are perioperative and postoperative complications, audiologic performance, and ABI electophysiologic parameters at 5 years from date of surgery. This study is currently recruiting participants with the estimated completion date of November Summary The Nucleus 24 Auditory Brainstem (ABI) Implant received FDA approval only for patients with neurofibromatosis type 2 (NF2) following tumor removal. The available evidence for unilateral use of ABI devices in patients with NF2 is sufficient to demonstrate improvements in net health outcomes. Therefore, the policy statement indicates an auditory brainstem implant may be considered medically necessary in this condition. ABIs hold promise for patients with cochlear and cochlear nerve abnormalities when cochlear implants are not indicated. However, studies on ABIs for non-nf2 conditions are limited, with small numbers of patients and insufficient data to make scientific conclusions. Given the lack of both high-quality evidence and FDA approval, ABI for non-nf2 conditions and bilateral ABI are considered investigational. Penetrating electrode auditory brainstem implant is also considered investigational, since the very limited evidence available is insufficient to draw conclusions on health outcomes. Practice Guidelines and Position Statements In January 2005, National Institute for Clinical Excellence (NICE) issued Interventional Procedure Guidance 108, Auditory Brain Stem Implants. (15) The guidance states the following: evidence on safety and efficacy of auditory brain stem implants appears adequate to support the use of this procedure by surgical teams experienced in this technique. Page 5
6 V. DEFINITIONS NEUROFIBROMA is a tumor of the connective tissue of the nerve. NEUROFIBROMATOSIS is a group of genetic disorders that affects the cell growth of neural tissues. NEUROFIBROMATOSIS TYPE II (NF-2) is an autosomal dominant disease affecting 1 in 50,000 persons and which causes intracranial and spinal tumors. VI. BENEFIT VARIATIONS The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member s individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member s benefit information or contact Capital for benefit information. VII. DISCLAIMER Capital s medical policies are developed to assist in administering a member s benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member s benefit information, the benefit information will govern. Capital considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law. VIII. REFERENCES 1. Nucleus 24 Auditory Brainstem Implant System. FDA Summary of Safety and Effectiveness. Available online at: Last accessed March 6, Ebinger K, Otto S, Arcaroli J et al. Multichannel auditory brainstem implant: US clinical trial results. J Laryngol Otol Suppl 2000; (27): Sanna M, Di Lella F, Guida M et al. Auditory brainstem implants in NF2 patients: results and review of the literature. Otol Neurotol 2012; 33(2): Goffi-Gomez MV, Magalhaes AT, Brito Neto R et al. Auditory brainstem implant outcomes and MAP parameters: report of experiences in adults and children. Int J Pediatr Otorhinolaryngol 2012; 76(2): Page 6
7 5. Colletti V, Fiorino FG, Carner M et al. Auditory brainstem implant as a salvage treatment after unsuccessful cochlear implantation. Otol Neurotol 2004; 25(4):485-96; discussion Colletti V, Carner M, Miorelli V et al. Auditory brainstem implant (ABI): new frontiers in adults and children. Otolaryngol Head Neck Surg 2005; 133(1): Colletti V. Auditory outcomes in tumor vs. nontumor patients fitted with auditory brainstem implants. Adv Otorhinolaryngol 2006; 64: Colletti L. Beneficial auditory and cognitive effects of auditory brainstem implantation in children. Acta Otolaryngol 2007; 127(9): Colletti V, Shannon RV, Carner M et al. Complications in auditory brainstem implant surgery in adults and children. Otol Neurotol 2010; 31(4): Sennaroglu L, Ziyal I, Atas A et al. Preliminary results of auditory brainstem implantation in prelingually deaf children with inner ear malformations including severe stenosis of the cochlear aperture and aplasia of the cochlear nerve. Otol Neurotol 2009; 30(6): Otto SR, Shannon RV, Wilkinson EP et al. Audiologic outcomes with the penetrating electrode auditory brainstem implant. Otol Neurotol 2008; 29(8): Sennaroglu L, Ziyal I. Auditory brainstem implantation. Auris Nasus Larynx 2012; 39(5): Colletti L, Shannon R, Colletti V. Auditory brainstem implants for neurofibromatosis type 2. Curr Opin Otolaryngol Head Neck Surg 2012; 20(5): Schwartz MS, Otto SR, Shannon RV et al. Auditory brainstem implants. Neurotherapeutics 2008; 5(1): National Institute for Clinical Excellence (NICE). Interventional Procedure Guidance 108. Auditory brain stem implants Available online at: Last accessed February Medicare Policy Benefit Manual. Chapter 16 - General Exclusions from Coverage. Available online at: Last accessed February 2013 Other: Taber s Cyclopedic Medical Dictionary, 19 th edition. IX. CODING INFORMATION Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement. Page 7
8 Covered when medically necessary: CPT Codes Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved. HCPCS Code L8699 S2235 Description Cochlear device, includes internal and external components Implantation of auditory brain stem implant ICD-9-CM Diagnosis Description Code* Neurofibromatosis Type 2 [acoustic neurofibromatosis ] *If applicable, please see Medicare LCD or NCD for additional covered diagnoses. The following ICD-10 diagnosis codes will be effective October 1, 2015: ICD-10-CM Diagnosis Description Code* Q85.02 Neurofibromatosis, type 2 *If applicable, please see Medicare LCD or NCD for additional covered diagnoses. X. POLICY HISTORY MP CAC 8/28/12 Information regarding auditory brain stem implants extracted from MP and this new policy created. Added investigational indications for all other conditions including non-neurofibromatosis-type. Coded 8/14/12 klr 04/22/2013- Admin code review. CAC 7/30/13 Consensus review. References updated, but no changes to the policy statements CAC 3/25/14 Consensus review. References updated, no changes to the policy statements. Rationale added. Policy coded. Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company, Capital Advantage Assurance Company and Keystone Health Plan Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies. Page 8
Original Policy Date
MP 7.01.66 Auditory Brainstem Implant Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy
More informationAuditory Brainstem Implant
Auditory Brainstem Implant Policy Number: 7.01.83 Last Review: 3/2018 Origination: 03/2017 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Auditory
More informationAuditory Brainstem Implant
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 1/1/2012 Most Recent Review Date (Revised): 1/18/2018 Effective Date: 8/1/2018 RETIRED POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationMEDICAL POLICY SUBJECT: COCHLEAR IMPLANTS AND AUDITORY BRAINSTEM IMPLANTS. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationClinical Commissioning Policy: Auditory brainstem implant with congenital abnormalities of the auditory nerves of cochleae
Clinical Commissioning Policy: Auditory brainstem implant with congenital abnormalities of the auditory nerves of cochleae Reference: NHS England: 16062/P NHS England INFORMATION READER BOX Directorate
More informationthe health outcomes or benefits associated with this procedure.
Original Issue Date (Created): October 4, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 I. POLICY Cognitive rehabilitation may be considered medically necessary for
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 3/1/2012 Most Recent Review Date (Revised): 9/6/2018 Effective Date: 11/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationClinical Policy: Cochlear Implant Replacements
Clinical Policy: Reference Number: CP.MP.14 Last Review Date: 07/18 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationMEDICAL POLICY SUBJECT: COCHLEAR IMPLANTS AND AUDITORY BRAINSTEM IMPLANTS
MEDICAL POLICY. PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationClinical Policy: Cochlear Implant Replacements Reference Number: CP.MP.14
Clinical Policy: Reference Number: CP.MP.14 Effective Date: 02/09 Last Review Date: 09/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and
More informationTo be considered medically necessary, an eligible provider must prescribe all orthotics.
Original Issue Date (Created): 2/1/2018 Most Recent Review Date (Revised): 9/26/2017 Effective Date: 4/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationMEDICAL POLICY POLICY TITLE T-WAVE ALTERNANS TESTING POLICY NUMBER MP
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY T-wave alternans is considered investigational as a technique
More informationMEDICAL POLICY I. POLICY POLICY TITLE POLICY NUMBER CANAKINUMAB (ILARIS ) MP-2.147
Original Issue Date (Created): May 1, 2010 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 I. POLICY Preauthorization is required for injectable Canakinumab (Ilaris ): Note:
More informationMedical Affairs Policy
Medical Affairs Policy Service: Cochlear Implants, Bone Anchored Hearing Aids (BAHA), Auditory Brainstem Implants, and Other Hearing Assistive Devices PUM 250-0014 Medical Policy Committee Approval 06/15/18
More informationCochlear Implant, Bone Anchored Hearing Aids, and Auditory Brainstem Implant
Origination: 06/23/08 Revised: 10/15/16 Annual Review: 11/10/16 Purpose: To provide cochlear implant, bone anchored hearing aids, and auditory brainstem implant guidelines for the Medical Department staff
More informationPediatric Use: Safety and effectiveness of Ustekinumab (STELARA ) in pediatric patients have not been evaluated.
Original Issue Date (Created): January 1, 2010 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Preauthorization Requirements for Ustekinumab (STELARA ) Note:
More information[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
Original Issue Date (Created): October 25, 2011 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Semi-implantable and fully implantable middle ear hearing
More informationCHAPTER. Auditory Brainstem Implants INTRODUCTION NEUROFIBROMATOSIS TYPE 2. Eric P Wilkinson, Steven R Otto, Marc S Schwartz, Derald E Brackmann
Author Query: 1. Please update the ref. 22. CHAPTER 34 Auditory Brainstem Implants Eric P Wilkinson, Steven R Otto, Marc S Schwartz, Derald E Brackmann INTRODUCTION The auditory brainstem implant (ABI)
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 26, 2013 Most Recent Review Date (Revised): November 26, 2013 Effective Date: April 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): April 24, 2012 Most Recent Review Date (Revised): May 20, 2014 Effective Date: August 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationCorporate Medical Policy
Corporate Medical Policy Cochlear Implant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cochlear_implant 2/1996 2/2017 2/2018 2/2017 Description of Procedure or Service A cochlear
More informationMEDICAL POLICY I. POLICY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 I. POLICY Laser treatment of port wine stains in the presence of functional impairment
More informationBone Anchored Hearing Aids (BAHA) and Partially-Implantable Magnetic Bone Conduction Hearing Aids
Bone Anchored Hearing Aids (BAHA) and Partially-Implantable Magnetic Bone Conduction Hearing Aids Policy Number: 2016M0023A Effective Date: 5/14/2018 Review Date: 4/27/2018 Next Review Date: 5/14/2020
More informationClinical Policy: Bone-Anchored Hearing Aid Reference Number: CP.MP.93
Clinical Policy: Reference Number: CP.MP.93 Effective Date: 12/13 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationIMPLANTABLE BONE-CONDUCTION AND BONE-ANCHORED HEARING AIDS
Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its
More informationCochlear Implant Corporate Medical Policy
Cochlear Implant Corporate Medical Policy File Name: Cochlear Implant & Aural Rehabilitation File Code: UM.REHAB.06 Origination: 03/2015 Last Review: 01/2019 Next Review: 01/2020 Effective Date: 04/01/2019
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): January 28, 2014 Most Recent Review Date (Revised): January 28, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedures overview of auditory brain stem implants Introduction This overview has been prepared to assist
More information[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
Original Issue Date (Created): May 3, 2004 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY Mechanical insufflation-exsufflation (MI-E) may be considered
More informationOpen Set Speech Perception with Auditory Brainstem Implant?
balt5/zln-lar/zln-lar/zln-orig/zln4793-05a shropsha S 4 8/29/05 8:02 Art: MLG200120 Input-nlm The Laryngoscope Lippincott Williams & Wilkins, Inc. 2005 The American Laryngological, Rhinological and Otological
More informationFor Professionals. Electrode Arrays. Designed for Atraumatic Implantation Providing Superior Hearing Performance
For Professionals Electrode Arrays Designed for Atraumatic Implantation Providing Superior Hearing Performance Electrode Arrays Designed for Atraumatic Implantation Providing Superior Hearing Performance,,,
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 26, 2013 Most Recent Review Date (Revised): November 26, 2013 Effective Date: April 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationMEDICAL POLICY I. POLICY II. PRODUCT VARIATIONS TOP III. DESCRIPTION/BACKGROUND POLICY TITLE SPHENOPALATINE GANGLION BLOCK POLICY NUMBER MP-4.
Original Issue Date (Created): 2/1/2018 Most Recent Review Date (Revised): 7/5/2018 Effective Date: 9/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationPublic Statement: Medical Policy Statement:
Medical Policy Title: Implantable Bone ARBenefits Approval: 09/28/2011 Conduction Hearing Aids Effective Date: 01/01/2012 Document: ARB0190 Revision Date: Code(s): 69714 Implantation, osseointegrated implant,
More informationIndications and contra-indications of auditory brainstem implants. Systematic review and illustrative cases
Manuscript: Authors: Journal: Indications and contra-indications of auditory brainstem implants. Systematic review and illustrative cases Merkus P (p.merkus@vumc.nl), Di Lella F, Di Trapani G, Pasanisi
More informationSubject: Implantable Bone-Conduction and Bone- Anchored Hearing Aids
02-69000-06 Original Effective Date: 08/15/03 Reviewed: 09/27/18 Revised: 10/15/18 Subject: Implantable Bone-Conduction and Bone- Anchored Hearing Aids THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION,
More informationHistory of Cochlear Implants and Auditory Brainstem Implants
Møller AR (ed): Cochlear and Brainstem Implants Adv Otorhinolaryngol Basel, Karger, 2006, vol 64, pp 1 10 History of Cochlear Implants and Auditory Brainstem Implants Aage R Møller School of Behavioral
More informationThe Auditory Brainstem Implant. Manchester Royal Infirmary
The Auditory Brainstem Implant Manchester Royal Infirmary What is an auditory brainstem implant (ABI)? An auditory brainstem implant (ABI) is a device that may allow a person to hear if they have had damage
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 30, 2013 Most Recent Review Date (Revised): May 20, 2014 Effective Date: August 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More information16:30-18:30 WS #52: Paediatric Forum (120mins - not repeated)
Dr Kate Gibson Clinical Geneticist Genetic Health Service NZ, Children s Specialist Centre, Christchurch Hospital, Christchurch Dr Antony Bedggood Ophthalmologist Children s Specialist Centre, Christchurch
More informationPaediatric cochlear implantation
Paediatric cochlear implantation A M U MÜLLER BA (Log), MSc (Sp&H) Senior Lecturer Department of Speech, Language and Hearing Therapy University of Stellenbosch D J H WAGENFELD MB ChB, MMed (L et O), FCS
More informationSympathetic Electrical Stimulation Therapy for Chronic Pain
Sympathetic Electrical Stimulation Therapy for Chronic Pain Policy Number: 015M0076A Effective Date: April 01, 015 RETIRED 5/11/017 Table of Contents: Page: Cross Reference Policy: POLICY DESCRIPTION COVERAGE
More informationCochlear implants. Carol De Filippo Viet Nam Teacher Education Institute June 2010
Cochlear implants Carol De Filippo Viet Nam Teacher Education Institute June 2010 Controversy The CI is invasive and too risky. People get a CI because they deny their deafness. People get a CI because
More informationCONFLICTS OF INTEREST
COCHLEAR IMPLANTATION: A SURGEON S PERSPECTIVE Ravi N. Samy, M.D., F.A.C.S. Ravi.Samy@UC.edu Director, Adult Cochlear Implant Program Program Director, Neurotology Fellowship CONFLICTS OF INTEREST RESEARCH
More informationSpecialised Services Policy:
Specialised Services Policy: CP35 Cochlear Implants Document Author: Specialised Planner for Women & Children s Services Executive Lead: Director of Planning Approved by: Executive Board Issue Date: 05
More informationBilateral Cochlear Implant Guidelines Gavin Morrison St Thomas Hearing Implant Centre London, UK
Bilateral Cochlear Implant Guidelines Gavin Morrison St Thomas Hearing Implant Centre London, UK Overview Audiometric Candidacy UK (NICE) & World Practices Auditory Implant Neurophysiology Results and
More informationCochlear Implants. What is a Cochlear Implant (CI)? Audiological Rehabilitation SPA 4321
Cochlear Implants Audiological Rehabilitation SPA 4321 What is a Cochlear Implant (CI)? A device that turns signals into signals, which directly stimulate the auditory. 1 Basic Workings of the Cochlear
More informationEXECUTIVE SUMMARY Academic in Confidence data removed
EXECUTIVE SUMMARY Academic in Confidence data removed Cochlear Europe Limited supports this appraisal into the provision of cochlear implants (CIs) in England and Wales. Inequity of access to CIs is a
More informationMedical Coverage Policy Cochlear Implants
Medical Coverage Policy Cochlear Implants EFFECTIVE DATE: 05 17 2017 POLICY LAST UPDATED: 09 04 2018 OVERVIEW A cochlear implant is a device for treatment of severe-to-profound hearing loss in individuals
More informationCONVENTIONAL AND DIGITAL HEARING AIDS
CONVENTIONAL AND DIGITAL HEARING AIDS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical
More informationImplantable Treatments for Different Types of Hearing Loss. Margaret Dillon, AuD Marcia Adunka, AuD
Implantable Treatments for Different Types of Hearing Loss Margaret Dillon, AuD Marcia Adunka, AuD Implantable Technologies Types of hearing loss Bone-anchored devices Middle ear implantation Cochlear
More informationREVIEW ARTICLE. Neurofibromatosis 2: hearing restoration options
Braz J Otorhinolaryngol. 2012;78(5):128-34. REVIEW ARTICLE Neurofibromatosis 2: hearing restoration options BJORL.org Tatiana Alves Monteiro 1, Maria Valeria Schmidt Goffi-Gomez 2, Robinson Koji Tsuji
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): January 28, 2014 Effective Date: August 20, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationCochlear Implants: The Role of the Early Intervention Specialist. Carissa Moeggenberg, MA, CCC-A February 25, 2008
Cochlear Implants: The Role of the Early Intervention Specialist Carissa Moeggenberg, MA, CCC-A February 25, 2008 Case Scenario 3 month old baby with a confirmed severe to profound HL 2 Counseling the
More informationDIAGNOSIS Causes/Etiology of Hearing Loss
DIAGNOSIS Causes/Etiology of Hearing Loss DIAGNOSIS Causes/Etiology of Hearing Loss VI. How Do We Hear? Sound waves enter our ears and are amplified by the ear drum and middle ear bones (ossicles), allowing
More informationBONE ANCHORED HEARING AID (BAHA) POLICY
BONE ANCHORED HEARING AID (BAHA) POLICY Please note that all Central Lancashire Clinical Commissioning policies are currently under review and elements within the individual policies may have been replaced
More informationMEDICAL POLICY SUBJECT: DENTAL AND ORAL CARE UNDER MEDICAL PLANS
MEDICAL POLICY SUBJECT: DENTAL AND ORAL CARE UNDER PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationSeries Preface. Preface. Acknowledgments. Abbreviations
Contents Series Preface Preface Acknowledgments Abbreviations vii ix xiii xxv Introduction xxxi Definition...xxxi Normal Hearing...xxxi Deafness...xxxi Overall Concept of the Bionic Ear...xxxii Training
More informationPurpose of Session. Discuss. Review. Medicare audiology coverage policy. Issues raised by transmittals Possible outcomes 11/24/2008
Purpose of Session Review Medicare audiology coverage policy 2008 Medicare audiologytransmittals Discuss Issues raised by transmittals Possible outcomes 1 Three Audiology Update Transmittals Transmittal
More informationCochlear Implant The only hope for severely Deaf
Cochlear Implant The only hope for severely Deaf By: Dr. M. Sohail Awan, FCPS (ENT) Aga Khan University Hospital, Karachi - Pakistan For centuries, people believed that only a miracle could restore hearing
More information9/13/2017. When to consider CI or BAHA evaluation? Krissa Downey, AuD, CCC A
When to consider CI or BAHA evaluation? Krissa Downey, AuD, CCC A FDA Regulations Unilateral or bilateral cochlear implantation of an FDA approved cochlear implant device may be considered medically necessary
More informationCorporate Medical Policy
Corporate Medical Policy Implantable Bone Conduction Hearing Aids File Name: Origination: Last CAP Review: Next CAP Review: Last Review: implantable_bone_conduction_hearing_aids 6/2006 2/2017 2/2018 2/2017
More information3/20/2017. D. Richard Kang, MD, FACS, FAAP Pediatric Otolaryngology Director, ENT Institute Boys Town National Research Hospital
D. Richard Kang, MD, FACS, FAAP Pediatric Otolaryngology Director, ENT Institute Boys Town National Research Hospital Pediatric providers have a reasonable chance to see a child with hearing loss in your
More informationCan You Hear Me Now? Learning Objectives 10/9/2013. Hearing Impairment and Deafness in the USA
Can You Hear Me Now? An update on the latest technology and solutions for hearing impairment Linda S. MacConnell, PA-C ENT Specialists of AZ ASAPA Fall CME Conference ctober, 03 Learning bjectives. Differentiate
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: July 24, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationCochlear Implant Innovations
HOSPITAL CHRONICLES 2011, 6(4): 195 199 Special Topic Matilda Chroni, MD, PhD, Spyros Papaspyrou, MD, PhD ENT Department, Evagelismos General Hospital of Athens, Athens, Greece Key words: cochlear implants;
More informationClinical Policy Title: Bone-anchored hearing aids and cochlear implants
Clinical Policy Title: Bone-anchored hearing aids and cochlear implants Clinical Policy Number: 10.03.02 Effective Date: June 1, 2014 Initial Review Date: January 15, 2014 Most Recent Review Date: January
More informationIntroduction to Cochlear Implants, Candidacy Issues, and Impact on Job Functioning. Definitions. Definitions (continued) John P. Saxon, Ph. D.
Introduction to Cochlear Implants, Candidacy Issues, and Impact on Job Functioning John P. Saxon, Ph. D., CRC Definitions Hearing impairment: means any degree and type of auditory disorder. Deafness: means
More informationMEDICAL POLICY PEGLOTICASE (KRYSTEXXA ) POLICY NUMBER MP POLICY TITLE. Original Issue Date (Created): January 1, 2011
Original Issue Date (Created): January 1, 2011 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY PREAUTHORIZATION REQUIRED Note: Requests for pegloticase
More informationCochlear implants. Aaron G Benson MD Board Certified Otolaryngologist Board Certified Neurotologist
Cochlear implants Aaron G Benson MD Board Certified Otolaryngologist Board Certified Neurotologist 1 OBJECTIVES WHAT IS A NEUROTOLOGIST WHAT MAKES AN INDIVIDUAL A COCHLEAR IMPLANT CANDIDATE WHAT IS THE
More informationMEDICAL POLICY I. POLICY. POLICY TITLE POLICY NUMBER OMALIZUMAB (XOLAIR ) MP-2.123
Original Issue Date (Created): May 3, 2004 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY. Note: Initial Authorization If the patient has been maintained
More informationManchester Adult Cochlear Implant Programme
Manchester Royal Infirmary Manchester Adult Cochlear Implant Programme Information for Patients and Professionals Contents Introduction 3 The normal ear 4 The cochlear implant 5 The assessment procedure
More informationClinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145
Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145 Effective Date: 05/17 Last Review Date: 06/17 See Important Reminder at the end of this policy for important regulatory
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): June 18, 2007 Most Recent Review Date (Revised): March 25, 2014 Effective Date: July 17, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationMEDICAL POLICY I. POLICY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 25, 2012 Effective Date: October 1, 2012 I. POLICY Cervicography Cervicography is considered investigational, as
More informationMEDICAL POLICY I. POLICY II. PRODUCT VARIATIONS POLICY TITLE POLICY NUMBER MANIPULATION UNDER ANESTHESIA MP-8.006
Original Issue Date (Created): October 04, 2003 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 I. POLICY Manipulation under anesthesia (MUA) may be considered medically
More informationBioscience in the 21st century
Bioscience in the 21st century Lecture 2: Innovations and Challenges Dr. Michael Burger Outline: Review of last lecture Organization of the nervous system (in brief) The mapping concept Bionic implants
More informationPeter S Roland M.D. UTSouthwestern Medical Center Dallas, Texas Developments
Peter S Roland M.D. UTSouthwestern Medical Center Dallas, Texas Developments New electrodes New speech processing strategies Bilateral implants Hybrid implants ABI in Kids MRI vs CT Meningitis Totally
More informationImaging in patients undergoing cochlear implant: CT and MR technique
Imaging in patients undergoing cochlear implant: CT and MR technique Poster No.: C-0102 Congress: ECR 2012 Type: Educational Exhibit Authors: G. Posillico Keywords: Ear / Nose / Throat, CT, MR, Comparative
More informationGlossary For Parents. Atresia: closure of the ear canal or absence of an ear opening.
Glossary For Parents This is not a complete or comprehensive glossary of audiologic and medical terms. It does include many technical and often unfamiliar terms that parents may hear used in connection
More informationPrior authorization is required for all hearing aids.
Hearing Aids MP9445 Covered Service: Prior Authorization Required: Additional Information: Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Prior authorization is required for all
More informationHEARING SERVICES CSHCN SERVICES PROGRAM PROVIDER MANUAL
HEARING SERVICES CSHCN SERVICES PROGRAM PROVIDER MANUAL AUGUST 2018 CSHCN PROVIDER PROCEDURES MANUAL AUGUST 2018 HEARING SERVICES Table of Contents 20.1 Enrollment......................................................................
More informationAuditory Brainstem Implantation After Unsuccessful Cochlear Implantation of Children With Clinical Diagnosis of Cochlear Nerve Deficiency
1338-033-E Annals of Otology, Rhinology & Laryngology 122(?):??-??. 2013 Annals Publishing Company. All rights reserved. Auditory Brainstem Implantation After Unsuccessful Cochlear Implantation of Children
More informationIHCP banner page INDIANA HEALTH COVERAGE PROGRAMS BR MARCH 1, 2016
IHCP banner page INDIANA HEALTH COVERAGE PROGRAMS BR201609 MARCH 1, 2016 IHCP creates separate Hearing Aid Dealer and Audiologist code sets Effective April 1, 2016, the Indiana Health Coverage Programs
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): June 4, 2013 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationWheaton Journal of Neuroscience Senior Seminar Research
Wheaton Journal of Neuroscience Senior Seminar Research Issue 1, Spring 2016: "Life 2.0: Blurring the Boundary Between our Tech and Ourselves" R.L. Morris, Editor. Wheaton College, Norton Massachusetts.
More informationPolicy #: 018 Latest Review Date: June 2014
Name of Policy: Cochlear Implants Policy #: 018 Latest Review Date: June 2014 Category: Surgery Policy Grade: A Background/Definitions: As a general rule, benefits are payable under Blue Cross and Blue
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): December 8, 2003 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationHearing the Universal Language: Music and Cochlear Implants
Hearing the Universal Language: Music and Cochlear Implants Professor Hugh McDermott Deputy Director (Research) The Bionics Institute of Australia, Professorial Fellow The University of Melbourne Overview?
More informationMedical Policy Hearing Devices. MassHealth* Connector/Qualified Health Plans* Authorization required X X No notification or authorization Not covered
Medical Policy Hearing Devices Document Number: 019 Commercial and MassHealth* Connector/Qualified Health Plans* Authorization required X X No notification or authorization Not covered * Not all plans
More informationOutcome of Cochlear Implantation at Different Ages from 0 to 6 Years
Otology & Neurotology 23:885 890 2002, Otology & Neurotology, Inc. Outcome of Cochlear Implantation at Different s from 0 to 6 Years Paul J. Govaerts, Carina De Beukelaer, Kristin Daemers, Geert De Ceulaer,
More informationHearing Loss Information and Solutions. When Hearing Aids Are Not Enough
Hearing Loss Information and Solutions When Hearing Aids Are Not Enough 2 Reconnect to a world of sound Are you missing conversations at dinner with your family? What about a meeting with co-workers in
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal Review of TA166; Deafness (severe to profound) - cochlear implants
More informationau/images/conductive-loss-new.jpg
Biology of the ear http://www.nal.gov. au/images/conductive-loss-new.jpg Agenda Pre-test Lecture Group Gesture Types of hearing losses Audiograms Views Post-test Pretest!! See how much you know Answer
More informationA Review of Cochlear Implantation in the Georgia Medicaid Population
A Review of Cochlear Implantation in the Georgia Medicaid Population Miller GM, Chelton LG, Choate S, Ariail D, Pedelty P Georgia Medical Care Foundation Atlanta, Georgia Georgia Medical Care Foundation
More information